A study adds new evidence that SARS-CoV-2—the virus that causes COVID-19—could have a lasting impact on the heart.
showing that people with hypertension may be at higher risk of heart events when they get COVID-19.
It’s also possible that viruses can infect and adversely affect heart cells. “We’re still at the tip of the iceberg with respect to understanding how COVID-19 affects health,” says Cheng. Ultimately, that knowledge will help to better treat people who might be at higher risk of heart-related problems from COVID-19, which could in turn reduce hospitalizations and deaths from the disease. Marks has already developed a potential drug that can address the leaking calcium if that proves to be a problem with COVID-19; he is ready and eager to test it if his animal studies justify the experiments.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Epidemic dynamics of the SARS-CoV-2 Omicron variant in China during the transition from 'zero-COVID' to little-to-no intervention effortsEpidemic dynamics of the SARS-CoV-2 Omicron variant in China during the transition from 'zero-COVID' to little-to-no intervention efforts medrxivpreprint LosAlamosNatLab Omicron COVID19 coronavirus covid
Read more »
The prevalence of spike-protein antibodies following at least 3 COVID-19 vaccine doses in immunocompromised individualsThe prevalence of spike-protein antibodies following at least 3 COVID-19 vaccine doses in immunocompromised individuals medrxivpreprint UniofNottingham unisouthampton imperialcollege KingsCollegeLon spikeprotein antibodies COVID19
Read more »
The relationship between antibody titers and incident SARS-CoV-2 infection among recipients of a primary vaccine seriesThe relationship between antibody titers and incident SARS-CoV-2 infection among recipients of a primary vaccine series medrxivpreprint Harvard DukeU JohnsHopkins Columbia Yale antibody infection SARSCoV2 vaccine
Read more »
Omicron has higher risk of in-hospital mortality compared to influenzaIn a recent study published in the journal JAMA Network Open, researchers compared the hospital outcomes of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant with those of influenza patients in Switzerland, assess the current disease burden due to coronavirus disease 2019 (COVID-19).
Read more »
The brain reacting to COVID-19: analysis of the cerebrospinal fluid proteome, RNA and inflammation - Journal of NeuroinflammationPatients with COVID-19 can have a variety of neurological symptoms, but the active involvement of central nervous system (CNS) in COVID-19 remains unclear. While routine cerebrospinal fluid (CSF) analyses in patients with neurological manifestations of COVID-19 generally show no or only mild inflammation, more detailed data on inflammatory mediators in the CSF of patients with COVID-19 are scarce. We studied the inflammatory response in paired CSF and serum samples of patients with COVID-19 (n = 38). Patients with herpes simplex virus encephalitis (HSVE, n = 10) and patients with non-inflammatory, non-neurodegenerative neurological diseases (n = 28) served as controls. We used proteomics, enzyme-linked immunoassays, and semiquantitative cytokine arrays to characterize inflammatory proteins. Autoantibody screening was performed with cell-based assays and native tissue staining. RNA sequencing of long-non-coding RNA and circular RNA was done to study the transcriptome. Proteomics on single protein level and subsequent pathway analysis showed similar yet strongly attenuated inflammatory changes in the CSF of COVID-19 patients compared to HSVE patients with, e.g., downregulation of the apolipoproteins and extracellular matrix proteins. Protein upregulation of the complement system, the serpin proteins pathways, and other proteins including glycoproteins alpha-2 and alpha-1 acid. Importantly, calculation of interleukin-6, interleukin-16, and CXCL10 CSF/serum indices suggest that these inflammatory mediators reach the CSF from the systemic circulation, rather than being produced within the CNS. Antibody screening revealed no pathological levels of known neuronal autoantibodies. When stratifying COVID-19 patients into those with and without bacterial superinfection as indicated by elevated procalcitonin levels, inflammatory markers were significantly (p | 0.01) higher in those with bacterial superinfection. RNA sequencing in the CSF revealed 101 linear RNAs comprising mess
Read more »
Research reports full efficacy of Sotrovimab against BQ.1.1 viral replication in a non-human primate challenge modelResearchers used a non-human primate model to show that Sotrovimab, a commercial mAb also known as Xevudy, was fully effective against SARS-CoV-2 Omicron BA.5 sub-lineage and its derivatives, such as BQ.1.1.
Read more »